Skip to content

EV / EBITDA at other companies

Kimberly-Clark logo
Kimberly-ClarkKMB
11.9×-1.8×
Procter & Gamble logo
Procter & GamblePG
15×-3.6×
The Honest Company logo
The Honest CompanyHNST
46.7×
Church & Dwight logo
Church & DwightCHD
18.7×-9.6×
Helen Of Troy logo
Helen Of TroyHELE
11.1×-0.6×
Bath & Body Works logo
Bath & Body WorksBBWI
5.6×-1.3×

Other financials

Income statement

See full
Revenue$519.5M+0.6%
Gross profit$216.9M-8.4%
Operating income$18.4M-62.4%
Net income-$10.6M-137%
EPS (diluted)-$0.22-137%

Balance sheet

See full
Cash & equivalents$299.7M+76.2%
Total debt$1.3B-13.4%
Total equity$1.4B-4.3%
Total assets$3.5B-6.4%

Cash flow

See full
Operating cash flow-$125.9M-8.9%
CapEx$14.0M-18.1%
Free cash flow-$137.5M-3.9%

Valuation

See full
Market cap$1.17B+7.5%
Enterprise value$2.15B-10.2%
P/S0.6×0.0×

Profitability

See full
Gross margin40.6%-2.8pp
Operating margin6.4%-3.8pp
Net margin3.1%-2.2pp
FCF margin-15.6%

Returns & leverage

See full
Return on equity4.1%-3.5pp
Debt / equity0.9×-0.1×
Current ratio1.8×-0.1×

Where this comes from

Calculated from Edgewell Personal Care’s reported figures.

Based on the most recent quarter.

The official record: Edgewell Personal Care’s 10-Q, filed August 5, 2025, on SEC EDGAR. View the filing →

Ask your AI about Edgewell Personal Care's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Edgewell Personal Care's EV / EBITDA?
Edgewell Personal Care (EPC) reported EV / EBITDA of 10.6× in Q2 2025.
How has Edgewell Personal Care's EV / EBITDA changed year-over-year?
Edgewell Personal Care's EV / EBITDA increased by 9.4% year-over-year, from 9.7× to 10.6×.
What is the long-term trend for Edgewell Personal Care's EV / EBITDA?
Over 4 years (2020 to 2024), Edgewell Personal Care's EV / EBITDA has grown at a 2.8% compound annual growth rate (CAGR), from 9.3× to 10.4×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.